Skip to content
Clinical Trials – home

Hospital Universitario Virgen De Valme

Research site

Spain Avenida Bellavista S/n, 41014 Sevilla, Spain

  • 43 trials recruiting
  • Non-small cell lung cancer · Non-small cell lung cancer metastatic · Systemic lupus erythematosus
  • Adults and children

About Specializations

Hospital Universitario Virgen De Valme in Sevilla, Spain specialises in clinical trials of conditions such as Non-small cell lung cancer, Non-small cell lung cancer metastatic, Systemic lupus erythematosus, Neoplasm malignant, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular and Metabolic Research

At Hospital Universitario Virgen De Valme, this research area focuses on cardiovascular diseases and related metabolic disorders, including atherosclerotic cardiovascular disease, chronic heart failure, and dyslipidemia. The trials are mainly designed to test new treatment options and better ways to reduce major heart-related risks and complications.

  • Studying treatments for chronic heart failure with reduced ejection fraction and related outcomes
  • Evaluating approaches for atherosclerotic cardiovascular disease and prevention of major cardiovascular events
  • Assessing therapies aimed at improving LDL cholesterol control in dyslipidemia

This line of research supports better prevention and long-term management of common heart and lipid disorders in patients treated at the site.

Autoimmune and Inflammatory Disease Studies

A major focus at the Servicio de Medicina Interna is immune system diseases, especially systemic lupus erythematosus, idiopathic inflammatory myopathy, psoriatic arthritis, and axial spondyloarthritis. These trials are exploring new therapies to control inflammation, improve symptoms, and assess longer-term safety in chronic autoimmune conditions.

  • Research on systemic lupus erythematosus to improve disease control and symptom relief
  • Trials in idiopathic inflammatory myopathy and psoriatic arthritis evaluating safety and effectiveness
  • Studies in axial spondyloarthritis and related inflammatory disorders aimed at better symptom management

The site is contributing to the development of more targeted options for patients living with persistent autoimmune disease.

Oncology and Cancer Treatment Research

The site conducts extensive neoplasm research across several cancer types, including non-small cell lung cancer, small cell lung cancer, breast cancer, endometrial cancer, colorectal cancer, bladder cancer, and chronic lymphocytic leukemia. These studies are designed to test new anticancer strategies, compare treatment effectiveness, and improve survival outcomes.

  • Investigating new treatment options for lung cancer, including advanced and mutation-defined subtypes
  • Studying early breast cancer and recurrence prevention after initial treatment
  • Evaluating therapies for endometrial cancer, colorectal cancer, bladder cancer, and chronic lymphocytic leukemia

This cancer portfolio reflects a strong interest in both earlier-stage disease and advanced tumors, with a clear emphasis on improving patient outcomes.

Respiratory, Infectious, and Hospital-Based Studies

Research at Hospital Universitario Virgen De Valme also includes respiratory tract diseases and virus diseases, with studies in COVID-19 and lung cancer-related respiratory conditions. These trials often aim to understand treatment benefit in hospitalized patients, reduce disease progression, and improve care during acute illness.

  • Clinical studies in COVID-19 focused on hospitalized patients with moderate to severe disease
  • Trials in respiratory cancers assessing new treatment combinations and survival outcomes
  • Hospital-based research aimed at improving outcomes in acute infectious and respiratory conditions

This area highlights the site's role in both pandemic-related research and complex respiratory disease management.

Digestive, Skin, and Other Specialized Clinical Research

The remaining studies cover a broad mix of digestive system diseases, skin and connective tissue diseases, and selected reproductive and urinary physiological phenomena. Key topics include ulcerative colitis, fertility-related research, and additional inflammatory conditions, with the goal of improving symptom control, treatment response, and patient quality of life.

  • Research in ulcerative colitis aimed at improving disease control in inflammatory bowel disease
  • Studies on male factor infertility exploring options to support conception
  • Additional work in skin and connective tissue and other less specific clinical areas

Together, these trials show a diverse internal medicine research program that extends beyond the major disease groups into other important clinical needs.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Avenida Bellavista S/n41014 SevillaSpain
Recruiting now
43 trials
Conditions studied
98

More sites in SevillaSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

153 clinical trials

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan Hydrochloride
  • Sponsor:Zai Lab (US) LLC

Evaluation of Anifrolumab Subcutaneous Treatment in Immunosuppressant‑Naïve and Biologic‑Naïve Patients with Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:BioNTech SE

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:BioNTech SE
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Phase 2 study of MK-7262 and enlicitide decanoate in adults with high lipoprotein(a)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Merck Sharp & Dohme LLC

Study of precemtabart tocentecan alone or in drug combination versus standard therapy in previously treated metastatic colorectal cancer patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Healthcare KGaA

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Study to evaluate the efficacy and safety of personalized tissue engineered veins in patients with severe chronic venous insufficiency

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic vein tissue segment, decellularised, with a functional valve perfused with autologous peripheral blood
  • Sponsor:VeriGraft AB

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
  • Sponsor:Novo Nordisk A/S
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.